242 related articles for article (PubMed ID: 29763816)
1. Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
Penny WF; Henry TD; Watkins MW; Patel AN; Hammond HK
Am Heart J; 2018 Jul; 201():111-116. PubMed ID: 29763816
[TBL] [Abstract][Full Text] [Related]
2. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial.
Hammond HK; Penny WF; Traverse JH; Henry TD; Watkins MW; Yancy CW; Sweis RN; Adler ED; Patel AN; Murray DR; Ross RS; Bhargava V; Maisel A; Barnard DD; Lai NC; Dalton ND; Lee ML; Narayan SM; Blanchard DG; Gao MH
JAMA Cardiol; 2016 May; 1(2):163-71. PubMed ID: 27437887
[TBL] [Abstract][Full Text] [Related]
3. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
Chung ES; Miller L; Patel AN; Anderson RD; Mendelsohn FO; Traverse J; Silver KH; Shin J; Ewald G; Farr MJ; Anwaruddin S; Plat F; Fisher SJ; AuWerter AT; Pastore JM; Aras R; Penn MS
Eur Heart J; 2015 Sep; 36(33):2228-38. PubMed ID: 26056125
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.
Borow KM; Yaroshinsky A; Greenberg B; Perin EC
Circ Res; 2019 Jul; 125(3):265-281. PubMed ID: 31318648
[TBL] [Abstract][Full Text] [Related]
6. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
[TBL] [Abstract][Full Text] [Related]
7. Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction.
Penny WF; Hammond HK
Hum Gene Ther; 2017 May; 28(5):378-384. PubMed ID: 28322590
[TBL] [Abstract][Full Text] [Related]
8. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction.
Zile MR; Lindenfeld J; Weaver FA; Zannad F; Galle E; Rogers T; Abraham WT
J Am Coll Cardiol; 2020 Jul; 76(1):1-13. PubMed ID: 32616150
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial.
Felker GM; Solomon SD; Claggett B; Diaz R; McMurray JJV; Metra M; Anand I; Crespo-Leiro MG; Dahlström U; Goncalvesova E; Howlett JG; MacDonald P; Parkhomenko A; Tomcsányi J; Abbasi SA; Heitner SB; Hucko T; Kupfer S; Malik FI; Teerlink JR
JAMA Cardiol; 2022 Jan; 7(1):26-34. PubMed ID: 34643642
[TBL] [Abstract][Full Text] [Related]
10. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).
Greenberg B; Yaroshinsky A; Zsebo KM; Butler J; Felker GM; Voors AA; Rudy JJ; Wagner K; Hajjar RJ
JACC Heart Fail; 2014 Feb; 2(1):84-92. PubMed ID: 24622121
[TBL] [Abstract][Full Text] [Related]
11. Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure.
Qayyum AA; Mouridsen M; Nilsson B; Gustafsson I; Schou M; Nielsen OW; Hove JD; Mathiasen AB; Jørgensen E; Helqvist S; Joshi FR; Johansen EM; Follin B; Juhl M; Højgaard LD; Haack-Sørensen M; Ekblond A; Kastrup J
ESC Heart Fail; 2023 Apr; 10(2):1170-1183. PubMed ID: 36638837
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
Udelson JE; McGrew FA; Flores E; Ibrahim H; Katz S; Koshkarian G; O'Brien T; Kronenberg MW; Zimmer C; Orlandi C; Konstam MA
J Am Coll Cardiol; 2007 Jun; 49(22):2151-9. PubMed ID: 17543634
[TBL] [Abstract][Full Text] [Related]
13. Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial.
Premchand RK; Sharma K; Mittal S; Monteiro R; Dixit S; Libbus I; DiCarlo LA; Ardell JL; Rector TS; Amurthur B; KenKnight BH; Anand IS
J Card Fail; 2014 Nov; 20(11):808-16. PubMed ID: 25187002
[TBL] [Abstract][Full Text] [Related]
14. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
Gheorghiade M; Böhm M; Greene SJ; Fonarow GC; Lewis EF; Zannad F; Solomon SD; Baschiera F; Botha J; Hua TA; Gimpelewicz CR; Jaumont X; Lesogor A; Maggioni AP;
JAMA; 2013 Mar; 309(11):1125-35. PubMed ID: 23478743
[TBL] [Abstract][Full Text] [Related]
15. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).
Rickenbacher P; Kaufmann BA; Maeder MT; Bernheim A; Goetschalckx K; Pfister O; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2017 Dec; 19(12):1586-1596. PubMed ID: 28295985
[TBL] [Abstract][Full Text] [Related]
16. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.
Jessup M; Greenberg B; Mancini D; Cappola T; Pauly DF; Jaski B; Yaroshinsky A; Zsebo KM; Dittrich H; Hajjar RJ;
Circulation; 2011 Jul; 124(3):304-13. PubMed ID: 21709064
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial).
Mathiasen AB; Jørgensen E; Qayyum AA; Haack-Sørensen M; Ekblond A; Kastrup J
Am Heart J; 2012 Sep; 164(3):285-91. PubMed ID: 22980293
[TBL] [Abstract][Full Text] [Related]
18. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Legg JC; Büchele G; Varin C; Kurtz CE; Malik FI; Honarpour N
JACC Heart Fail; 2020 Apr; 8(4):329-340. PubMed ID: 32035892
[TBL] [Abstract][Full Text] [Related]
19. Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.
Linde C; Daubert C; Abraham WT; St John Sutton M; Ghio S; Hassager C; Herre JM; Bergemann TL; Gold MR;
Circ Heart Fail; 2013 Nov; 6(6):1180-9. PubMed ID: 24014828
[TBL] [Abstract][Full Text] [Related]
20. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
